AbbVie Inc

ABBV

Equity

ISIN US00287Y1091 / Valor 20145667

New York Stock Exchange, Inc (2025-04-04)

USD 186.96-7.28%

AbbVie Inc
UMushroom community rating:

4.50 2 votes No rating yet

NegativeNeutralPositive

About company

AbbVie Inc. is a global biopharmaceutical company dedicated to researching, developing, and marketing innovative medicines and medical solutions. With a workforce of over 50,000 employees across more than 70 countries, AbbVie focuses on addressing complex health challenges and improving the quality of life for people around the world. The company has a significant presence in research and development (R&D) and manufacturing, with facilities in approximately 20 countries. AbbVie's portfolio includes treatments for over 75 conditions, and its products reach around 50 million people annually in 175 countries. The company also emphasizes collaboration, maintaining over 250 partnerships with biotech firms, universities, nonprofits, and government organizations to advance scientific discovery. AbbVie's commitment to innovation is underscored by its development pipeline, which includes more than 80 compounds, devices, or indications.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Growth

In the fourth quarter of 2024, AbbVie Inc. reported worldwide net revenues of $15.102 billion, marking an increase of 5.6 percent on a reported basis and 6.1 percent on an operational basis. This growth was driven by strong performances across several of its key portfolios, including immunology and neuroscience.

Immunology Portfolio

AbbVie Inc.'s immunology portfolio generated global net revenues of $7.294 billion in the fourth quarter of 2024, reflecting a 4.9 percent increase on a reported basis. Notably, Skyrizi and Rinvoq showed significant growth, with Skyrizi's revenues increasing by 57.7 percent and Rinvoq's by 46.2 percent.

Oncology and Neuroscience Performance

The oncology portfolio of AbbVie Inc. saw global net revenues of $1.691 billion, a 12.0 percent increase on a reported basis. Meanwhile, the neuroscience portfolio achieved $2.509 billion in global net revenues, representing a 19.8 percent increase, driven by strong performances from Botox Therapeutic and Vraylar.

Profitability Metrics

For the fourth quarter of 2024, AbbVie Inc. reported a diluted loss per share of $0.02 on a GAAP basis, which included an intangible asset impairment charge. However, the adjusted diluted EPS was $2.16, excluding specified items, despite an unfavorable impact of $0.88 per share related to acquired IPR&D and milestones expense.

2025 Outlook

Looking ahead, AbbVie Inc. has provided a 2025 adjusted diluted EPS guidance range of $12.12 to $12.32, excluding any unfavorable impact related to acquired IPR&D and milestones expense. The company reaffirms its expectations for a high single-digit compound annual revenue growth rate through 2029, with a raised 2027 sales outlook for Skyrizi and Rinvoq to more than $31 billion.

Summarized from source with an LLMView Source

Key figures

11.4%1Y

15.5%3Y

155%5Y

Performance

25.7%1Y

22.8%3Y

23.0%5Y

Volatility